Membranoproliferative glomerulonephritis following tubulointerstitial nephritis is a late manifestation of IgG4-related kidney disease: A distinctive case
Publication date: November 2019Source: Human Pathology: Case Reports, Volume 18Author(s): Joichi Usui, Steven P. Salvatore, Mourhege Alsaloum, Alla Goldberg, Sheng Kuo, Surya V. SeshanAbstractIgG4-related kidney disease (IgG4RKD) generally presents as an active and chronic fibrosing tubulointerstitial nephritis. Recent reports have described glomerular lesions, typically with IgG4 containing subepithelial/membranous deposits as part of IgG4RKD. Herein, we report a case of IgG4-related membranoproliferative glomerulonephritis and associated tubulointerstitial nephritis in the clinical setting of IgG4-related autoimmune disease. A 75-year-old male diabetic patient with renal dysfunction showed IgG4-related tubulointersitital nephritis (TIN) superimposed on mild diabetic nephropathy by renal biopsy and was on 2 months of steroid therapy. Three years later, he developed progressive renal failure and heavy proteinuria leading to a second biopsy which showed, IgG4-dominant membranoproliferative pattern of glomerulonephritis (MPGN) along with chronic fibrosing IgG4-related tubulointerstitial disease. The development of MPGN is a rare lesion in association with IgG4 related TIN and may represent a late manifestation of IgG4RKD or continued complement activation.
This study aims to validate this observation. Blood levels of seven cytokines were measured in 120 patients with pSS from the United Kingdom Primary Sjögren’s Syndrome Registry and 30 age-matched healthy non-fatigued controls. Patient-reported scores for fatigue were classified acco rding to severity and compared to cytokine levels using analysis of variance. The differences between cytokines in cases and controls were evaluated using Wilcoxon test. A logistic regression model was used to determine the most important identifiers of fatigue. Five cytokines, interferon-γ-induced protein-10 (IP-10), tumour ne...
AbstractA false-positive result of syphilis screening test (FPST) is a characteristic finding in patients with systemic lupus erythematosus (SLE). We evaluated the clinical characteristics of SLE patients with FPST at SLE diagnosis. We reviewed the medical records of patients with SLE who underwent the Venereal Disease Research Laboratory or Rapid Plasma Reagin tests at SLE diagnosis at Severance Hospital between 2006 and 2016. The baseline characteristics and clinical outcomes were compared between patients with FPST and those with a negative result of syphilis screening test. Of 145 patients with SLE, 20 patients showed ...
First study of its kind to show that although low doses of statins appear protective of bone health, high doses may increase risk for osteoporosis.Medscape Medical News
Treatment with mifepristone resulted in increased levothyroxine requirements among patients with Cushing disease and central hypothyroidism.Journal of the Endocrine Society
Authors: Fernández-Vidal M, Canllavi Fiel E, Bada Bosch T, Trujillo Cuéllar H, García Martín F, Gutiérrez Martínez E, Molina Gómez M, Alonso Riaño M, Praga Terente M PMID: 31606161 [PubMed - as supplied by publisher]
- Collaboration combines Abbott ′s world-leading glucose sensing technology with Omada Health's best-in-class, proprietary digital coaching platform to provide personalized, on-the-go care
DiabetesMine shares a story of how the Native American population is fighting off diabetes, in the face of diet and cultural challenges.
Abbott (NYSE: ABT) and Omada Health announced today they are partnering to integrate Abbott's revolutionary FreeStyle Libre system, a continuous glucose monitoring (CGM) technology, with Omada Health's pioneering digital care program, aiming to create a new paradigm for people with Type 2 diabetes.
TYPE 2 diabetes requires careful monitoring to ward off the risk of rising blood sugar levels. Certain dietary choices have been shown to control blood sugar levels, including a certain seed.
Conclusion As a critical regulator of inflammation and cell survival, the NFκB pathway is a promising target for diagnosing and treating kidney diseases. For modulation of the NFκB pathway in the clinic, a number of molecules can effectively inhibit NFκB signaling by targeting the receptors, associated adaptors, IKKs, IκBs and transcriptional regulators (144). There is further clinical evidence on small-molecule inhibitors of IKKα and NIK from recent trials on anti-cancer therapies (145). These clinical trials showed that the cancer-selective pharmacodynamic response of DTP3, the co-inhibitor...